A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

Inclusion Criteria:

1. Signed consent obtained before any study-related activities (study-relatedactivities are any procedure related to recording of data according to theprotocol).

2. The decision to initiate treatment with commercially available Sogroya (somapacitan)has been made by the participant and the treating physician before and independentlyfrom the decision to include the participant in this study.

3. Male or female, age above or equal to 18 years assigned to Sogroya (somapacitan)treatment at the time of signing informed consent.

4. Diagnosis of adult growth hormone deficiency (AGHD) as per local practice.

Exclusion Criteria:

1. Previous participation in this study. Participation is defined as signed informedconsent.

2. Mental incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation.

3. Participant with hypersensitivity to the active substance or to any of theexcipients.

4. Participant with active malignancy or in treatment for active pre-existingmalignancy.

5. Participant with acute critical illness, suffering from complications following openheart surgery, abdominal surgery, multiple accidental trauma, acute respiratoryfailure or similar conditions per investigator judgement.